핵의학

본문글자크기
  • [Clin Nucl Med.] 유방암 림프절 FDG섭취에 따른 예후 The Prognostic Value of 18F-FDG Uptake in the Supraclavicular Lymph Node (N3c) on PET/CT in Patients With Locally Advanced Breast Cancer With Clinical N3c.

    연세의대 / 이석현, 김성훈, 윤미진*

  • 출처
    Clin Nucl Med.
  • 등재일
    2019 Jan
  • 저널이슈번호
    44(1):e6-e12. doi: 10.1097/RLU.0000000000002365.
  • 내용

    바로가기  >

    Abstract
    PURPOSE:
    We investigated the prognostic value of F-FDG uptake in the supraclavicular lymph node (SCLN) on PET/CT in breast cancer patients with clinical ipsilateral SCLN metastasis (cN3c).

    METHODS:
    Fifty-five female patients with initial F-FDG PET/CT were treated with curative intent. For semiquantitative analysis, the SUVmax of the primary tumor, axillary lymph node, and SCLN were normalized by the SUVmean of the liver (defined as SUVR-tumor, SUVR-axillary lymph node, and SUVR-SCLN, respectively). Cox proportional hazards models were used to predict disease-free survival (DFS) and overall survival (OS). Differences in DFS and OS were assessed by Kaplan-Meier analysis.

    RESULTS:
    Twenty-three patients (41.8%) experienced recurrence, and 13 (23.6%) died during follow-up (median, 70.0 months; range, 6-128 months). In multivariate analysis, SUVR-tumor greater than 3.26 (hazards ratio, 7.26; 95% confidence interval, 1.58-33.31; P = 0.01) and SUVR-SCLN greater than 1.05 (hazards ratio, 8.47; 95% confidence interval, 1.09-65.87; P = 0.04) were prognostic for OS. No clinicopathologic or PET/CT parameters were prognostic for DFS. The patients were divided into 3 groups: group 1 (n = 11, SUVR-tumor ≤3.26 and SUVR-SCLN ≤1.05); group 2 (n = 27, SUVR-tumor >3.26 or SUVR-SCLN >1.05); and group 3 (n = 17, SUVR-tumor >3.26 and SUVR-SCLN >1.05). The 5-year OS rates were 100% in group 1, 85.2% in group 2, and 51.0% in group 3. Group 3 showed worse prognosis than group 1 (P < 0.01) and group 2 (P < 0.01).

    CONCLUSIONS:
    In addition to SUVR-tumor, SUVR-SCLN seemed to play an important role in selecting patients with the worst prognosis.

     


    Author information

    Lee SH1, Kim SH1, Park HS2, Kim JH2, Kim D1, Cho H1, Yun M1.
    1
    From the Departments of Nuclear Medicine, and.
    2
    Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

  • 덧글달기
    덧글달기
       IP : 3.139.70.131

    등록